Header Logo

Connection

Summer Dewdney to Tumor Suppressor Protein p53

This is a "connection" page, showing publications Summer Dewdney has written about Tumor Suppressor Protein p53.
Connection Strength

0.472
  1. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 10 01; 40(28):3289-3300.
    View in: PubMed
    Score: 0.193
  2. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
    View in: PubMed
    Score: 0.176
  3. Use of cervical mucus to screen for gynecological malignancies: a pilot study. Mod Pathol. 2013 Nov; 26(11):1508-13.
    View in: PubMed
    Score: 0.104
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.